© 2025 | Vesselon®
Press Release
Vesselon Expands Leadership Team: Pharma Industry Veteran Parviz Gharamani Named Senior EVP, Head of Research & Development
Blog
Betting on Bubble Technology: From Alzheimer’s Treatment to Enhanced Cancer Drug Delivery
Blog
Overview: Vesselon’s Transformative Co-formulation Method
Blog
Emerging Dynamics in the Biopharmaceutical Industry: Mergers & Acquisitions Trends
The Scientist
How Vesselon Can Improve the Entire Class of Radiopharmaceuticals
The Scientist
How Vesselon Can Improve the Entire Class of Antibody-Drug Conjugates
Press Release
Vesselon Virtual Town Hall: A Glimpse into the Future of Intravenous Drug Development
Press Release
Introducing the First On-site Co-Formulation Platform that Dramatically Improves How Cells Receive and Act on Drugs
Press Release
Vesselon Protects and Expands Drug Franchises
Drug maker is seeking strategic relationship to deliver unprecedented levels of efficacy by making tissues more receptive to drugs.
Drug Discovery Trends
Merck and Vesselon Preclinical Study Reports Dramatic Tumor Pharmacokinetics Findings
Complete regression of both primary and distant tumors in 44% of enrolled subjects achieved with intravenous administration.
BioSpace
Vesselon Acquires FDA Approved Lipid Microsphere Imagent
“By changing the rate of progression or stopping cancer in its tracks, Vesselon can change the cancer landscape.”
Advanced Therapeutics
Sonoporation-Enhanced Delivery of STING Agonist Induced Robust Immune Modulation & Tumor Regression
Sonoporation, the temporal cell membrane openings that can arise after ultrasound exposure, has been explored across many preclinical applications but has lacked translational momentum.